Africa: WHO Prequalifies First African-Made Combination Therapy for Seasonal Malaria Chemoprevention

[Universal Corporation Ltd] Geneva and Kiambu -- Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, becomes the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product. Sulfadoxine-pyrimethamine + amodiaquine (SPAQ) is a combination drug used to prevent malaria in children living in areas of seasonal malaria transmission. The combination therapy is employed in seasonal malaria chemoprevention (SMC) programmes and is designed to protect
Source: AllAfrica News: Malaria - Category: Infectious Diseases Tags: Africa Health and Medicine Malaria Source Type: news